CCN2 and acute lymphoblastic leukemia: Similar findings were reported in a smaller study on 33 adult ALL patients with relapsed or refractory disease; CCN2 expression was not predictive for complete remission rate nor for resistant disease, but there was a trend for patients with higher expression of CCN2 in circulating lymphoblasts to have an inferior overall survival (Advani et al. 2010).